Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3499-3506

  Chen, Guan ^a,b   Teicher, Beverly A ^a   Frei III, Emil ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; LOSOXANTRONE; OXANTHRAZOLE; PACLITAXEL; PROTEIN INHIBITOR; THALICARPINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APORPHINES; BENZYLISOQUINOLINES; BREAST NEOPLASMS; DOXORUBICIN; DRUG INTERACTIONS; ETOPOSIDE; HUMANS; ISOQUINOLINES; P-GLYCOPROTEIN; PACLITAXEL; PYRAZOLES; PYRAZOLONES; TUMOR CELLS, CULTURED;

EID: 0030513617     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Biedler JL: Drug resistance: genotype versus phenotype - thirty-second G. H. A. Clowes Memorial Award Lecture. Cancer Res 54: 666-678, 1994.
2. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in viro and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
4. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-159, 1990.
5. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
6. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP and Salmon SE: Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105-110, 1991.
7. Sikic BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635, 1993.
8. Kartner N, Evernden-Porelle D, Bradley G and Ling V: Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820-823, 1985.
9. Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, van der School E, Balm AJM, Meijer CJLM, Broxterman HJ, Kuiper CM, Lankelma J and Pinedo HM: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int J Cancer 42: 389-394, 1988.
10. Volm M, Bak MJ, Efferth T and Mattern J: Induced multidrug resistance in murine leukemia L1210 and associated changes in a surfance membrane glycoprotein. J Cancer Res Clin Oncol 115: 17-24, 1989.
11. Fugua SAW, Moretti-Rojas IM, Schneider SL and McGuire WL: Pglycoprotein expression in human breast cancer cells. Cancer Res 47: 2103-2106, 1987.
12. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S and Mori S: Tissue distribution of p-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody. MRK16. Cancer Res 48: 1926-1929, 1988.
13. Venelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R and Chassagne J: Clinical relevance of immunohistochemical detection of multidrug resistance p-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111-116, 1991.
14. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz M, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB and Coon JS: Relationship of the expression of the multidrng resistance gene product (p-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
15. Holzmayer TA, Hilsenbeck S, von Hoff DD and Roninson IB: Clinical correlates of MDR1 (pglycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491, 1992.
16. Dexter DL and Leith JT: Tumor heterogeneity and drug resistance. J Clin Oncol 4: 244-257, 1986.
17. Kupchan SM, Chakravarti KK, Yokoyoma N: Thalicarpine, a new hypotensive alkaloid from Thalictrum dasycarpum. J Pharm Sci 52: 985-988, 1963.
18. Todorov DK: Thaliblastine. Drugs of the Future 13: 234-238, 1988.
19. Chen G, Todorov DK and Zeller WJ: Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cells sensitive and resistant to cisplatin. Cancer Lett 62: 173-177, 1988.
20. Chen G, Zeller WJ and Todorov DK: Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. Anticancer Res 13: 1269-1276, 1993.
21. Chen G, Ramachandran C and Krishan A. Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to pglycoprotein. Cancer Res 53: 2544-2547, 1993.
22. Chen G and Waxman DJ: Complete reversal by thaliblastine (TBL) of 490fold adriamycin (AdR) resistance in multidrug resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. J Pharmacol Exp Ther 274: 1271-1277, 1995.
23. Beck WT: Mechanisms of multidrug resistance in human tumor cells. The roles of p-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 17(Suppl. A): 11-20, 1990.
24. Rowinsky EK, Cazenave LA and Donehower RC: Taxol; a novel investigational antimicrotuble agent. J Natl Cancer Inst 82: 1247-1259, 1990.
25. Judson IR: The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin Oncol 19: 687-694, 1992.
26. Batist G, Tulpule A, Sinha BK, Katkis AG, Myers CE and Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrugresistant human breast cancer cells. J Biol Chem 267: 15544-15541, 1986.
27. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Pong J, Rosen N, Israel MA, Melera PW, Cowan KH and Coldmith EM: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancel cells. Cancer Res 47: 5141-5148, 1987.
28. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-65, 1983.
29. Kramer RA, Zakher J and Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697, 1988.
30. Morrow CS and Cowan KH: Editorial: Multidrug resistance associated with altered topoisomerase II activity - topoisomerase II as targets for rational drug design. J Natl Cancer Inst 82: 638-639, 1990.
31. Sinha BK, Haim N, Durse L, Kerrigan D and Pommier Y: DNA strand breaks produced by etoposide (VP-16, 213) in sensitive and resistant human breast tumor cells: Implications for the mechanisms of action. Cancer Res 48: 5096-5100, 1988.
32. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22, 665-667, 1979.
33. Chang AY, Kim K, Glick J, Anderson T, Karp D and Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-smallcell lung cancer: the eastern cooperative oncology group results. J Natl Cancer Inst 85: 388-394, 1993.
34. Holmes FA, Walters R, Theriault RL, Forman AD, Newton LK, Raher MN, Buzdar AU, Frye DK and Hortobagyi ON: Phase II trial of taxol an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
35. Liehmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (taxol) in human cell lines. Br J Cancer 68: 1104-1109, 1993.
36. Liehmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: The influence of cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331339, 1994.
37. Danesi R, Figg WD, Reed E and Myers CE: Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 47: 1106-1111, 1995.
38. Dou QP and Lui WY: Failure to dephosphorilate retinoblastoma protein in drug-resistant cells. Cancer Res 55: 5222-5225, 1995.
39. Cowan KH, Batist G, Tulpule A, Sinha BK and Myers CE: Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Acad Sci USA 83: 9328-9332, 1986.
40. Creaven PJ, Allen LM and Williams CP: The interaction of the antineoplastic drug thalicarpine with aniline hydroxylase and microsomal cytochrome of rat liver. Xenobiotica 4: 255-261, 1974.
41. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I and Wright H M: Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54: 386-392, 1994
42. Jachez B, Nordmann R and Loor F: Restoration of taxol sensitivity of multidrug resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85: 478-483, 1993.
43. Talbot DC, Smith IE, Judson MI, Calver AH and Ashley SE: Anthrapyrazol CI941: a highly active new agent in the treatment of advanced breast cancer. J Clin Oncol 9: 2141-2147, 1991.
44. Klohs WD, Steinkampf RW, Havlick MJ and Jackson RC: Resistance to anthrapyrazols and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res 46: 4352-4356, 1986.